India to Russia: Anastrozole Export Trade Route

To import Anastrozole formulations into Russia, the product must be registered with Roszdravnadzor. The registration process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. The standard timeline for registration is approximately 210 calendar days, excluding the duration required for clinical trials. During this period, the dossier undergoes a thorough review, encompassing document evaluation, production process assessment, and sample testing. Clinical trials must comply with the requirements established by federal law and other regulatory acts of Russia. The registration process also entails fees for expert review and the issuance of the registration certificate. Additionally, foreign manufacturing facilities are subject to Good Manufacturing Practice (GMP) inspections to ensure compliance with Russian standards. These inspections are conducted by the Ministry of Industry and Trade of the Russian Federation, and a GMP certificate is a prerequisite for product registration.

Indian exporters of Anastrozole formulations must hold GMP certifications that align with Russian standards. Since April 2016, the Ministry of Industry and Trade of the Russian Federation has been conducting inspections of foreign pharmaceutical manufacturers to verify compliance with Russian GMP requirements. These inspections are essential for drug registration and market access in Russia. Common violations identified during these inspections include deficiencies in quality management systems, inadequate documentation practices, and non-compliance with production protocols. Indian manufacturers aiming to export to Russia should ensure their facilities meet these stringent GMP standards to avoid regulatory actions such as suspension or revocation of licenses.

In January 2024, India's Ministry of Health revised its Good Manufacturing Practice (GMP) regulations to align more closely with global standards, including those of the World Health Organization (WHO). The updated rules introduced a pharmaceutical quality system (PQS), quality risk management (QRM), product quality review (PQR), and validation of equipment. These enhancements aim to ensure the production of high-quality, globally acceptable drugs. For Indian exporters targeting the Russian market, adherence to these updated GMP standards is crucial, as they reflect a commitment to quality that is likely to be favorably viewed by Russian regulatory authorities. Additionally, in March 2025, the Russian Ministry of Health proposed amendments to the rules for introducing medicines into civil circulation. Starting from September 2024, manufacturers are required to confirm the quality of each batch of pharmaceutical substances with Roszdravnadzor. This change underscores the importance of stringent quality control measures for all pharmaceutical products entering the Russian market.

Anastrozole is a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. The demand for Anastrozole formulations in Russia is influenced by several factors:

• Breast Cancer Prevalence: Breast cancer remains one of the most common cancers among women in Russia. In 2024, the incidence rate was approximately 50 cases per 100,000 women, underscoring a significant patient population requiring Anastrozole therapy.

• Healthcare Expenditure: Russia's healthcare spending has been on an upward trajectory, with a 5% increase in 2024 compared to the previous year. This rise enhances access to cancer treatments, including Anastrozole formulations.

• Aging Population: The proportion of the Russian population aged 60 and above reached 22% in 2024, a demographic more susceptible to breast cancer, thereby elevating the demand for Anastrozole.

• Universal Health Coverage: Russia's commitment to universal health coverage ensures that essential medications like Anastrozole are accessible to a broader segment of the population.

Regarding supply, Russia imports a significant portion of its Anastrozole formulations, with India being a notable supplier. Domestic production exists but does not fully meet the national demand, necessitating reliance on imports to bridge the gap.

Pharmaceutical imports under HS code 30049099, including Anastrozole formulations, are subject to the following tax structure in Russia:

• Import Duty: 0% (MFN rate)

• Value-Added Tax (VAT): 10%

There are no Free Trade Agreements (FTAs) between India and Russia that specifically affect pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on Anastrozole formulations imported from India.

India is a key supplier of Anastrozole formulations to Russia, accounting for approximately 1.7% of India's total Anastrozole formulation exports, valued at $1.8 million USD. Other major countries supplying Anastrozole to Russia include:

• European Union (EU) Manufacturers: Countries such as Germany and the United Kingdom are significant exporters of Anastrozole formulations to Russia.

• China: China also contributes to the supply of Anastrozole formulations in the Russian market.

India's share of Russia's total Anastrozole imports is substantial, reflecting its competitive position in the market. Pricing comparisons indicate that Indian Anastrozole formulations are competitively priced relative to those from EU manufacturers and China, offering cost-effective options without compromising on quality.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Anastrozole, such as tablets and capsules. The country's cost-effective production is attributed to economies of scale, a well-established supply chain, and a skilled workforce. As of 2024, India boasts 396 facilities registered under the U.S. FDA's Generic Drug User Fee Amendments (GDUFA), underscoring its compliance with international quality standards. Additionally, numerous Indian manufacturing plants hold WHO-GMP certifications, ensuring adherence to global good manufacturing practices.

When comparing Anastrozole formulations from India, China, and the European Union (EU), several factors emerge:

• Price per Unit: Indian manufacturers offer Anastrozole formulations at competitive prices due to lower production costs. Chinese products are similarly priced but may face higher logistical expenses. EU-manufactured formulations are typically more expensive, reflecting higher labor and operational costs.

• Quality Perception: Indian pharmaceutical products are widely recognized for their quality, with many facilities holding international certifications. Chinese products have improved in quality but may still encounter skepticism in certain markets. EU products are generally perceived as high-quality but come at a premium price.

• Regulatory Acceptance in Russia: India's pharmaceutical exports to Russia have been substantial, indicating strong regulatory acceptance. Chinese products also have a presence but may face more stringent scrutiny. EU products are readily accepted but are less competitive price-wise.

• Supply Reliability: Indian manufacturers have a proven track record of reliable supply chains, supported by robust infrastructure and regulatory compliance. Chinese suppliers have improved but may still experience occasional disruptions. EU suppliers are reliable but may have longer lead times and higher costs.

The India-Russia supply chain for Anastrozole formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging facilities. Indian manufacturers have demonstrated consistent compliance with international regulatory standards, including WHO-GMP and U.S. FDA approvals. For instance, Granules India Limited received U.S. FDA approval for its Hyderabad facility in November 2025, enhancing its finished dosage manufacturing capabilities. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Top Indian manufacturers continue to expand their capacities to meet growing global demand.

For Russian buyers sourcing Anastrozole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, commonly including letters of credit or advance payments, to ensure smooth financial transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet regulatory and quality standards.

• Regulatory Compliance: Ensure that selected suppliers have the necessary certifications and approvals required for the Russian market to facilitate seamless importation and distribution.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $10,000 to $15,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 4 to 6 weeks, including scheduling, on-site inspection, and reporting.

By adhering to this comprehensive framework, Russian companies can ensure the selection of reliable Indian suppliers for Anastrozole formulations, maintaining high standards of product quality and regulatory compliance.